GenVec (GNVC) Up After FDA Grants Orphan Drug Designation for TNFerade
More News related to GNVC
- GenVec (GNVC) Reports In-line Results for Q3
- GenVec Reports Third Quarter 2009 Financial Results
- SAIC-Frederick Signs $22M Contract with GenVec (GNVC) for Flu and HIV Vaccine Development
- GenVec Signs New Contract to Support HIV and Influenza Vaccine Development
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
More News related to FDA
- Transcept Pharma (TSPT) to Meet with U.S. FDA To Discuss NDA Response Letter for Intermezzo
- DARA BioSciences (DARA) Says Clinical Trial on KRN5500 Achieved Its Primary Endpoint
- Nymox Pharmaceutical (NYMX) Announces Positive Clinical Data on BPH Drug NX-1207
- ARCA Biopharma (ABIO) Annouces Gencaro OK'd by U.S. FDA for Fast Track Program
- Ception and Cephalon (CEPH) Report Initial Results from Phase IIb/III Trial for CINQUIL(TM)
GenVec Inc. (Nasdaq: GNVC) is 20% higher in pre-open action today after the company announced that hte FDA has granted orphan drug designation to TNFerade for the treatment of pancreatic cancer.
"Orphan drug designation is a critical step for the development of TNFerade and will strengthen the TNFerade program at GenVec by offering potential clinical development and commercialization benefits," stated Dr. Paul Fischer, GenVec's President and CEO.
Related Categories
FDAMomentum Movers
Stocks Mentioned
+0.06Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
